Inceptionr LLC Acquires 1,478 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Inceptionr LLC raised its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 21.8% during the fourth quarter, Holdings Channel reports. The firm owned 8,273 shares of the medical device company’s stock after buying an additional 1,478 shares during the period. Inceptionr LLC’s holdings in Tandem Diabetes Care were worth $298,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Baillie Gifford & Co. grew its position in Tandem Diabetes Care by 235.7% in the fourth quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after acquiring an additional 523,843 shares during the period. GW&K Investment Management LLC boosted its stake in shares of Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock valued at $76,488,000 after purchasing an additional 323,674 shares in the last quarter. Bellevue Group AG grew its holdings in shares of Tandem Diabetes Care by 19.9% in the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company’s stock worth $78,496,000 after purchasing an additional 307,624 shares during the last quarter. Stephens Investment Management Group LLC increased its position in shares of Tandem Diabetes Care by 22.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock worth $56,040,000 after purchasing an additional 281,327 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Tandem Diabetes Care by 397.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 301,614 shares of the medical device company’s stock valued at $11,121,000 after purchasing an additional 240,966 shares during the last quarter.

Wall Street Analyst Weigh In

TNDM has been the topic of several research analyst reports. Barclays decreased their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Citigroup cut Tandem Diabetes Care from a “buy” rating to a “neutral” rating and dropped their price target for the company from $35.00 to $24.00 in a report on Tuesday, March 4th. Robert W. Baird cut their price objective on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. Sanford C. Bernstein cut Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $22.00 price target (down from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $45.38.

Tandem Diabetes Care Stock Down 4.1 %

Shares of Tandem Diabetes Care stock opened at $17.96 on Monday. The business has a fifty day simple moving average of $33.17 and a 200 day simple moving average of $35.46. The stock has a market cap of $1.19 billion, a PE ratio of -9.31 and a beta of 1.45. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12 month low of $17.92 and a 12 month high of $53.69.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.